Clinical Trials

Intramuscular Ketamine Pharmacokinetics: Clinical Insights

A comprehensive review of intramuscular ketamine's pharmacokinetics reveals dose-dependent effects and highlights research gaps.

Published May 29, 2026 Read 1 min 262 words By The Psychedelic Journal

Ketamine's Expanding Role in Clinical Settings

Ketamine, a well-established anesthetic, is gaining traction for new clinical applications, particularly in resource-limited settings where intramuscular administration is favored. This review synthesizes existing studies on the pharmacokinetics of intramuscular ketamine, providing insights into its dose-dependent nature and bioavailability.

Pharmacokinetic Mechanisms and Variability

Intramuscular ketamine's pharmacokinetics exhibit a dose-dependent relationship, with plasma concentrations increasing linearly from 27 ng/mL at 0.1 mg/kg to 1970 ng/mL at 6.0 mg/kg. The time to reach maximal plasma concentration varies between 10 to 30 minutes, largely independent of the dose. Bioavailability remains inconsistent, reported between 41.1% and 93.0%, indicating significant variability that complicates dosing strategies.

Research Gaps and Clinical Implications

The review identifies a critical gap in pharmacokinetic data for higher doses of intramuscular ketamine, particularly above 1.0 mg/kg. This gap presents challenges in optimizing dosing for emerging clinical uses, such as in mental health treatments and pain management, where precise dosing is crucial for efficacy and safety.

Risks and Uncertainties

Despite its potential, ketamine's use is not without risks. The variability in bioavailability and absorption, especially in children who may exhibit faster absorption rates, underscores the need for tailored dosing strategies. Uncertainty about the long-term effects of ketamine, particularly at higher doses, necessitates cautious advancement in its clinical applications.

Future Directions in Ketamine Research

As ketamine's clinical uses expand, further research is essential to fill existing data gaps, particularly concerning higher doses and diverse patient populations. Such research will be pivotal in developing safe, effective dosing guidelines that can be applied across various clinical scenarios, including emergency and low-resource settings.

Primary source: https://openalex.org/W7162811839 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.